bDMARD positive and negative sentiment for efficacy and side effects
| bDMARD positive sentiment | ||||||
| bDMARD | Efficacy posts | Total positive posts | Percentage | Posts stating ‘no side effects’ | Total number of positive posts | Percentage |
| Infliximab | 2239 | 2636 | 84.94 | 308 | 2636 | 11.68 |
| Abatacept | 666 | 774 | 86.04 | 109 | 774 | 14.08 |
| Adalimumab | 3769 | 4419 | 85.29 | 616 | 4419 | 13.94 |
| Certolizumab | 383 | 461 | 83.08 | 76 | 461 | 16.49 |
| Golimumab | 264 | 306 | 86.27 | 48 | 306 | 15.69 |
| Rituximab | 777 | 918 | 84.64 | 143 | 918 | 15.58 |
| Tocilizumab | 335 | 384 | 87.24 | 51 | 384 | 13.28 |
| Tofacitinib | 281 | 346 | 81.21 | 70 | 346 | 20.23 |
| Etanercept | 4536 | 5210 | 87.06 | 610 | 5210 | 11.71 |
| bDMARD negative sentiment | ||||||
| bDMARD | Lack of efficacy posts | Total negative posts | Percentage | Side effects posts | Total negative posts | Percentage |
| Infliximab | 1265 | 2405 | 52.60 | 983 | 2405 | 40.87 |
| Abatacept | 437 | 694 | 62.97 | 259 | 694 | 37.32 |
| Adalimumab | 2500 | 4107 | 60.87 | 1429 | 4107 | 34.79 |
| Certolizumab | 249 | 415 | 60 | 163 | 415 | 39.28 |
| Golimumab | 187 | 243 | 76.95 | 53 | 243 | 21.81 |
| Rituximab | 347 | 615 | 56.42 | 243 | 615 | 39.51 |
| Tocilizumab | 143 | 274 | 52.19 | 132 | 274 | 48.18 |
| Tofacitinib | 102 | 202 | 50.5 | 102 | 202 | 50.50 |
| Etanercept | 2344 | 3852 | 60.85 | 1387 | 3852 | 36.00 |
bDMARD, biological disease modifying anti-rheumatic drug.